The FDA Vaccines and Related Biological Products Advisory Committee agreed on the efficacy, immunogenicity and safety data of Merck & Co Inc’s . The clinical trials support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and men aged 9 to 26 years for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

After two years of its approval, the Advisory Committee on Immunization Practices has detected no major problems with the safety of the HPV vaccine, Gardasil. The vaccine is used to protect against infection caused by the sexually transmitted virus, the HPV, that leads to genital warts and cervical cancer. The Center for Disease Control and Prevention has recommended the vaccination of girls at the age of 11 (much before they turn sexually active). No serious side effects have been found.